New Delhi, Sept. 26 -- India's pharmaceutical exports are not expected to face a major impact following the recent announcement of a 100 per cent tariff on branded and patented pharmaceutical products by the US, said Sudarshan Jain, General Secretary of the Indian Pharmaceutical Alliance (IPA).

Speaking to ANI on Friday, Jain said that India's exports to the US primarily consist of generic drugs and active pharmaceutical ingredients (APIs), which are not covered under this tariff.

"This [100 per cent tariff on imported pharmaceutical drugs] is applicable to patented branded products manufactured outside the US. It is not applicable to generics, and India supplies mostly generic products to the US. India exports around USD 10 billion wor...